MedPath

Diltiazem

Generic Name
Diltiazem
Brand Names
Cardizem, Cartia, Matzim, Taztia, Tiadylt, Tiazac
Drug Type
Small Molecule
Chemical Formula
C22H26N2O4S
CAS Number
42399-41-7
Unique Ingredient Identifier
EE92BBP03H
Background

Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as nifedipine, that preferentially act on vascular smooth muscle and verapamil that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities. Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.

Indication

Oral

Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.

Indicated for use to improve exercise tolerance in patients with chronic stable angina.

Indicated for the management of variant angina (Prinzmetal's angina).

Intravenous

Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.

Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.

Off-label

Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.

Associated Conditions
Angina Pectoris, Variant, Anginal Pain, Atrial Fibrillation, Atrial Flutter, Chronic Stable Angina Pectoris, Dilated Cardiomyopathies, Idiopathic, Fissure;Anal, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Proteinuria, Pulmonary Hypertension (PH), Leg cramps, Prophylaxis of migraine headaches

Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter

Phase 4
Completed
Conditions
Heart Rate and Rhythm Disorders
Interventions
First Posted Date
2013-08-02
Last Posted Date
2014-05-15
Lead Sponsor
Antonios Likourezos
Target Recruit Count
54
Registration Number
NCT01914926
Locations
🇺🇸

Maimonides Medical Center, Brooklyn, New York, United States

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Phase 1
Completed
Conditions
Atherosclerosis
Interventions
First Posted Date
2013-05-13
Last Posted Date
2017-07-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
36
Registration Number
NCT01852565
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

Phase 1
Conditions
Skin Irritation
Interventions
Drug: Vehicle Cream
Drug: 0.1% solution o sodium lauryl sulfate (SLS)
Drug: Saline 0.9%
First Posted Date
2013-03-29
Last Posted Date
2013-08-21
Lead Sponsor
Ventrus Biosciences, Inc
Target Recruit Count
30
Registration Number
NCT01821274
Locations
🇺🇸

TKL Research, Paramus, New Jersey, United States

An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride

Phase 1
Conditions
Adult Subjects With Anal Fissures.
Interventions
First Posted Date
2013-03-22
Last Posted Date
2013-08-21
Lead Sponsor
Ventrus Biosciences, Inc
Target Recruit Count
12
Registration Number
NCT01816191
Locations
🇺🇸

Wake Research Associates, Raleigh, North Carolina, United States

Topical Safety Study of Topical Diltiazem Hydrochloride

Phase 1
Conditions
Diltiazem Skin Sensitivity.
Interventions
Drug: Saline (0.9%)
Drug: Vehicle Cream
Drug: 0.1% solution of sodium lauryl sulfate (SLS)
First Posted Date
2013-03-22
Last Posted Date
2013-08-21
Lead Sponsor
Ventrus Biosciences, Inc
Target Recruit Count
200
Registration Number
NCT01816529
Locations
🇺🇸

TKL Research, Paramus, New Jersey, United States

Ischaemia-réperfusion During the Coronary Surgery With Beating Heart

Phase 3
Conditions
Ischaemia-reperfusion Injury
Interventions
Drug: Placebo
Drug: Acetylcystein
First Posted Date
2013-01-18
Last Posted Date
2013-01-18
Lead Sponsor
University Hospital, Strasbourg, France
Target Recruit Count
120
Registration Number
NCT01771978
Locations
🇫🇷

Department of Anaesthesiology, Strasbourg, France

Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Phase 3
Completed
Conditions
Chronic Anal Fissures
Interventions
Drug: Placebo
First Posted Date
2012-09-21
Last Posted Date
2014-01-23
Lead Sponsor
Ventrus Biosciences, Inc
Target Recruit Count
434
Registration Number
NCT01690221
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

Investigative Clinical Research, Annapolis, Maryland, United States

🇺🇸

Advance Medical Research Center, Miami, Florida, United States

and more 97 locations

Rate Control in Atrial Fibrillation

Phase 4
Completed
Conditions
Rapid Ventricular Response Atrial Fibrillation
Interventions
First Posted Date
2012-08-01
Last Posted Date
2012-08-01
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
90
Registration Number
NCT01655303
Locations
🇮🇷

Rasoul-e-Akram Hospital, Tehran, Iran, Islamic Republic of

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Not Applicable
Withdrawn
Conditions
Primary Pulmonary Hypertension
Familial Primary Pulmonary Hypertension
Idiopathic Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2012-07-20
Last Posted Date
2018-11-20
Lead Sponsor
University of South Florida
Registration Number
NCT01645826
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

Phase 1
Completed
Conditions
Drug Induced Constipation
Interventions
First Posted Date
2012-05-09
Last Posted Date
2014-10-15
Lead Sponsor
AstraZeneca
Target Recruit Count
44
Registration Number
NCT01594619
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath